The Prescription Drug Monitoring Program (PDMP) aims to improve the District’s ability to identify and reduce diversion of prescription drugs in an efficient and cost effective manner that will not impede the appropriate medical utilization of controlled substances; and to enhance patient care by providing prescription monitoring information that will assure legitimate use of controlled substances in health care, including palliative care, research and other medical and pharmacological uses.
PDMP Database Access
DC PDMP Presentation:
Click here to watch a presentation about the DC PDMP
For dispensers: As of June 7, 2019, gabapentin is a covered substance for the DC PDMP. Dispensers are required to report dispensations of gabapentin to the DC PDMP.
NEW! All licensed prescribers and dispensers must register for the DC Prescription Drug Monitoring Program by July 31, 2019. Read the notice to practitioners or FAQs about mandatory registration for full details.
New! DC PDMP User Survey: This survey will be used to gauge initial PDMP use by registered users after the mandatory registration. The information will be used to make improvements based off user feedback. Please take a few minutes complete the DC PDMP User Survey https://www.surveymonkey.com/r/DCPDMPSURVEY.
Gateway Integration - grant funding is available for integration of PDMP data into electronic health records (EHRs), health information exchanges (HIEs), and pharmacy management systems.
- Prescription Drug Monitoring Program Law
- Prescription Drug Monitoring Program Final Rulemaking
- Frequently Asked Questions
- Frequently Asked Questions for Mandatory Registration
- Annual Report
- PDMP Advisory Committee
In response to COVID-19, the District of Columbia Prescription Drug Advisory Committee meeting scheduled for April 21, 2020 is now CANCELED. If you have questions regarding the Coronavirus, please visit https://dchealth.dc.gov/page/health-notices and https://coronavirus.dc.gov/.
All questions and press inquiries regarding the Prescription Drug Monitoring Program must be submitted in writing. Interested parties may send inquiries by email to [email protected] or by regular mail to:
Prescription Drug Monitoring Program
Health Regulation and Licensing Administration
899 N. Capitol Street, NE
Washington, DC 20002